Integra LifeSciences reported a revenue of $442.6 million for Q4 2024, an 11.5% increase compared to Q4 2023. GAAP earnings per diluted share were $0.25, while adjusted earnings per diluted share were $0.97.
Reported revenues increased by 11.5% on a reported basis and 3.5% on an organic basis compared to Q4 2023.
GAAP earnings per diluted share were $0.25, the same as in Q4 2023.
Adjusted earnings per diluted share were $0.97, compared to $0.89 in Q4 2023.
Codman Specialty Surgical revenues increased by 15.8%, while Tissue Technologies revenues increased by 2.1%.
For the full-year 2025, the Company expects revenues to be in the range of $1,650 million to $1,715 million, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $2.41 and $2.51.
Analyze how earnings announcements historically affect stock price performance